Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19

被引：2

作者：

Junsen Chen ^{[1
]}

Rui Huang ^{[1
]}

Yiwen Nie ^{[1
]}

Xinyue Wen ^{[1
]}

Ying Wu ^{[1
,2
]}

机构：

[1] State Key Laboratory of Virology, School of Basic Medical Sciences, Wuhan University

[2] Hubei Province Key Laboratory of Allergy and Immunology

来源：

Virologica Sinica | 2020年 / 35卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R392-33 [免疫学技术、设备及实验方法];

学科分类号：

100102 ;

摘要：

Coronavirus disease 2019(COVID-19), reminiscent of the severe acute respiratory syndrome(SARS) outbreak in 2003,has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies.

引用

页码：713 / 724

页数：12

共 3 条

[1]

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections[J] . Tianlei Ying,Haoyang Li,Lu Lu,Dimiter S. Dimitrov,Shibo Jiang. Microbes and Infection . 2014

[2]

Structural basis for potent neutralization of betacoronaviruses by single-domain Camelid antibodies .2 Wrapp D,De Vlieger D,Corbett KS,Torres GM,Wang N,Van Breedam W,Roose K,van Schie L,Hoffmann M,Pohlmann S,Graham BS,Callewaert N,Schepens B,Saelens X,McLellan JS. Cell . 2020

[3]

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 .2 Ibarrondo FJ,Fulcher JA,Goodman-Meza D,et al. N Engl J Med . 2020

← 1 →